CITATION REPORT List of articles citing

The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research

DOI: 10.1007/s40263-016-0349-0 CNS Drugs, 2016, 30, 603-28.

Source: https://exaly.com/paper-pdf/65243283/citation-report.pdf

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
45	The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP. <i>Epilepsy Research</i> , 2017 , 137, 139-144	3	18
44	Brief report of efficacy and side effect profile of crossing over to modified-release capsules of methylphenidate in ADHD patients receiving other treatments: case series. <i>Journal of Theoretical Social Psychology</i> , 2017 , 27, 256-262	1.2	
43	Central Nervous System Stimulants and Drugs That Suppress Appetite. <i>Side Effects of Drugs Annual</i> , 2017 , 1-8	0.2	
42	Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder. <i>BioMed Research International</i> , 2018 , 2018, 4067597	3	25
41	Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. <i>Translational Pediatrics</i> , 2018 , 7, 36-47	4.2	22
40	Behandlung von ADHS bei Erwachsenen mit Atomoxetin. <i>Psychopraxis Neuropraxis</i> , 2019 , 22, 129-133	0.1	
39	Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder. <i>Current Hypertension Reports</i> , 2019 , 21, 60	4.7	4
38	Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. <i>Pediatrics</i> , 2019 , 144,	7.4	275
37	Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder: Part 1: Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular Repolarization. <i>Cardiology in Review</i> , 2019 , 27, 113-121	3.2	2
36	Current follow-up practices often fail to detect metabolic and neurological adverse reactions in children treated with second-generation antipsychotics. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020 , 109, 342-348	3.1	2
35	Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts. <i>Biological Psychiatry</i> , 2020 , 88, 452-458	7.9	9
34	Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases. <i>Molecules</i> , 2020 , 25,	4.8	11
33	Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder. <i>Antioxidants</i> , 2020 , 9,	7.1	20
32	ADHS im Kindes- und Jugendalter. Update 2020. Padiatrie Und Padologie, 2020, 55, 1-22	О	
31	Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder. <i>Antioxidants</i> , 2020 , 9,	7.1	15
30	Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children. <i>Paediatric Drugs</i> , 2021 , 23, 55-7	734.2	4
29	ADHD: Reviewing the Causes and Evaluating Solutions. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	7

28	ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	3
27	Lifetime evolution of ADHD treatment. <i>Journal of Neural Transmission</i> , 2021 , 128, 1085-1098	4.3	1
26	Evidence-based pharmacological treatment options for ADHD in children and adolescents. <i>Pharmacology & Therapeutics</i> , 2021 , 107940	13.9	4
25	Effects of methylphenidate on blood pressure, QT-interval, and cardiac output in ADHD diagnosed children: A three monthsSfollow-up study. <i>IJC Heart and Vasculature</i> , 2021 , 34, 100805	2.4	
24	Perpetration of and Victimization in Cyberbullying and Traditional Bullying in Adolescents with Attention-Deficit/Hyperactivity Disorder: Roles of Impulsivity, Frustration Intolerance, and Hostility. International Journal of Environmental Research and Public Health, 2021, 18,	4.6	1
23	Self-Reported Depressive Symptoms and Suicidality in Adolescents with Attention-Deficit/Hyperactivity Disorder: Roles of Bullying Involvement, Frustration Intolerance, and Hostility. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	0
22	ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan. <i>Current Medicinal Chemistry</i> , 2019 , 26, 6942-6969	4.3	8
21	Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. <i>Psychiatry Investigation</i> , 2018 , 15, 649-654	3.1	2
20	The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (III) - Pharmacological Treatment 2017 , 28, 70-83		5
19	Basics of Psychopharmacological Management. 2018,		
18	The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review <i>Frontiers in Psychiatry</i> , 2021 , 12, 780921	5	O
17	Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021 , 31, 699-703	3 ^{2.9}	O
16	Growth Hormone and Thyroid Function in Children with Attention-Deficit/Hyperactivity Disorder Undergoing Drug Therapy <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022 ,	5.6	0
15	Pregnancy and Breastfeeding. 679-721		
14	Hepatic and Renal Impairment. 723-754		1
13	Children and Adolescents. 539-599		
12	Personalization of pharmacological treatments for ADHD: Why it is advisable and possible options to achieve it <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	0
11	Nonstimulant Treatments for ADHD. Child and Adolescent Psychiatric Clinics of North America, 2022,	3.3	1

Medication and Substance-Induced Hypertension: Mechanisms and Management. 2022, 1-19

9	A meta-analytic review of the impact of ADHD medications on anxiety and depression in children and adolescents. <i>European Child and Adolescent Psychiatry</i> ,	5.5	
8	Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2022 , 31, 553-568	3.3	О
7	Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. 2022, 10,		Ο
6	Eating Patterns and Dietary Interventions in ADHD: A Narrative Review. 2022, 14, 4332		2
5	The management of attention-deficit hyperactivity disorder in children: updated 2022. 2022 , 3, 121-131		O
4	No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRx.		O
3	Long-term treatment of adult ADHD in a naturalistic setting: clinical predictors of attrition, medication choice, improvement, and response. 1-25		O
2	Medication and Substance-Induced Hypertension: Mechanisms and Management. 2023, 683-700		О
1	A Potential Role for Neuroinflammation in ADHD. 2023 , 327-356		O